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Abstract
Adjuvant chemotherapy decisions in breast cancer are increasingly based on the pathologist’s assessment of tumor
proliferation. The Swiss Working Group of Gyneco- and Breast Pathologists has surveyed inter- and intraobserver
consistency of Ki-67-based proliferative fraction in breast carcinomas.
Methods: Five pathologists evaluated MIB-1-labeling index (LI) in ten breast carcinomas (G1, G2, G3) by counting and
eyeballing. In the same way, 15 pathologists all over Switzerland then assessed MIB-1-LI on three G2 carcinomas, in self-
selected or pre-defined areas of the tumors, comparing centrally immunostained slides with slides immunostained in the
different laboratoires. To study intra-observer variability, the same tumors were re-examined 4 months later.
Results: TheKappa valuesfor thefirst seriesof tencarcinomasof various degreesof differentiationshowed good to very good
agreement for MIB-1-LI (Kappa 0.56–0.72). However, we found very high inter-observer variabilities (Kappa 0.04–0.14) in the
read-outs of the G2 carcinomas. It was not possible to explain the inconsistencies exclusively by any of the following factors: (i)
pathologists’ divergent definitions of what counts as a positive nucleus (ii) the mode of assessment (counting vs. eyeballing),
(iii)immunostainingtechnique,and(iv)theselectionofthe tumorareainwhichtocount.Despite intensiveconfrontation ofall
participating pathologists with the problem, inter-observer agreement did not improve when the same slides were re-
examined 4 months later (Kappa 0.01–0.04) and intra-observer agreement was likewise poor (Kappa 0.00–0.35).
Conclusion: Assessment of mid-range Ki-67-LI suffers from high inter- and intra-observer variability. Oncologists should be
aware of this caveat when using Ki-67-LI as a basis for treatment decisions in moderately differentiated breast carcinomas.
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Introduction
The last twenty years have witnessed a marked decline in breast
cancer mortality, largely due to earlier diagnosis, a better
understanding of the disease, and the advent of ever more
effective adjuvant treatment options [1,2]. This progress in
adjuvant systemic therapy has led to consensus recommendations
proposing adjuvant therapy to virtually all breast cancer patients
[3]. At the same time, we have to acknowledge that in order for
some patients to benefit from these adjuvant therapies, many
others are treated with little or no benefit – except for untoward
effects [4]. Chemotherapy targets proliferating tumor cells, high
proliferative activity of breast carcinomas predicts response to
chemotherapy [5,6] as well as endocrine therapy [7], and a drop in
proliferative activity after short-term neoadjuvant endocrine
therapy predicts prolonged disease-free survival [8].
Proliferative activity has historically been assessed by counting
mitotic figures at high magnification as well as by immunohisto-
chemical detection of Ki-67, a nuclear protein that is expressed in
proliferating cells [9]. In the light of the important prognostic and
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surprising that immunohistochemical detection of Ki-67 using the
MIB-1 antibody has gained increasing importance in routine
breast cancer diagnosis and has recently been recommended by
the St.Gallen consensus conference [10,11]. MIB-1-based prolif-
erative fraction of breast carcinomas thus can be taken into
consideration when defining an adjuvant treatment plan for
cancer patients. This decision is eather straightforward in large,
poorly differentiated carcinomas showing many (atypical) mitotic
figures or in small, highly differentiated carcinomas where only
scarce mitotic figures are found. These cases typically show a high
MIB-1 labelling index (LI) of more than 30% and a low MIB-1-LI
of less than 5%, respectively. In contrast, the putative chemother-
apy benefit may be more difficult to judge in moderately
differentiated carcinomas. Recent gene signature data suggest
that these G2 carcinomas can be separated into two categories,
with biological behaviors similar to either G1 or G3 carcinomas
[12]. This separation of G2 carcinomas into ‘‘pets’’ and ‘‘raptors’’
is defined by genes that drive tumor proliferation and could be
reproduced with high statistical power using immunhistochemical
detection of Ki-67 [11–15]. This has recently been designated the
‘‘tip effect ‘‘ that MIB-1-LI may play in moderately differentiated
carcinomas with indefinite prognosis [15].
For these reasons, oncologist have high expectations in the
MIB-1-LI, notably for patients with G2 carcinomas. Yet, how
reliable is the immunohistochemical technique and how reliable
are pathologists in assessing MIB-1 based proliferative activity in
individual patients? The present study was designed as a quality
control measure within the Working Group of Breast- and
Gynaecopathologists in the Swiss Society of Pathology to
investigate how accurate and reliable Ki-67 fractions are in
moderately differentiated carcinomas.
Materials and Methods
Cases were selected from the archives of the Department of
Surgical Pathology, University Hospital Zu ¨rich. The study was
submitted to the local Instituitional Review board and complied
with institutional guidelines. Immunohistochemical stains were
created from paraffin blocks in a strictly anonymized fashion. No
patient consent was required.
The study evolved in three steps. Between each step, all
pathologists participated in joint discussions of the results and the
study protocol.
Step one
Ten random cases of invasive breast carcinomas (two G1
carcinomas, five G2 carcinomas, and three G3 carcinomas) [16]
were immunostained with MIB-1 according to standard protocols
(DAKO M7240, 1:20) using the Ventana automated Benchmark
staining system (Ventana, Tucson, AZ) and sent to five patholo-
gists (central immunostain). In addition, one unstained slide of
each case was provided that the participating pathologists were
asked to immunostain in their own laboratories (local immuno-
stain). They were asked to quantify MIB-1-LI by rough estimation
(eyeballing) and by counting MIB-1 positive tumor cells among a
total of 2000 cells. No guidelines were given as to where (within the
tumor) to count and what exactly constitutes a MIB-1 positive
nucleus. Also, it was left to the pathologists to decide whether they
first counted MIB-1 positive cells or whether they first estimated
their percentage, as long as they made sure that the result of one
quantification technique did not affect the results on the
corresponding other technique. This was done by first eyeballing
all the cases in random order and then counting all the cases in
random order, or vice versa.
Step two
Three G2 breast carcinomas, showing a rather uniform
proliferative activity, were sent to 15 pathologists all of whom
regularly attended the meetings of the Working Group. For each
case, participants received one slide stained in Zu ¨rich (central
immunonstain) and one empty slide which he/she immunostained
in their own laboratory. In addition, an envelope was provided,
which had to be opened only after each pathologist had evaluated
the MIB-1-LI on the six slides in areas of the tumor that he/she
had selected him/herself. This envelope contained a digital picture
of each slide with five circled areas, in which MIB-1-LI had to be
assessed one more time. Participants were asked to provide MIB-1-
LI results by eye-balling and by counting positive tumor cells
among 500 tumor cells. In addition, each participant received a
letter-sized ‘‘intensity’’ plate containing 6 color images of MIB1-
stained slides (final magnification: 150 mm6150 mm, Figure 1A),
on which he/she was asked to count all MIB-1-positive and all -
negative tumor cells.
Step three
With the aim to improve reproducibility of MIB-1 read-outs, we
repeated step two four months later, but this time provided clear
guidelines (i) where within a tumor MIB-1-LI should be analysed
(in the tumor periphery, avoiding hot-spots), and (ii) what exactly
constitutes a MIB-1 positive nucleus. To this end, the ‘‘intensity’’
plate was distributed, on which all positive nuclei were circled
upon consultation with Pr. Giuseppe Viale (Figure 1B). To the
three G2 carcinomas used in step two, we added three new
carcinomas (G1, G2, G3).
Statistical analysis
Statistical analyses were performed using online calculators,
http://amchang.net/StatTools/CohenKappa_Pgm.php for
Fleiss’s and Cohen’s Kappa, and http://www.wessa.net/
rwasp_spearman.wasp for Spearman linear correlations. To
calculate Kappa values, MIB-1-LI data were stratified into a
three-tier scoring system, using arbitrary cut-offs of 8% (G1 vs. G2)
and 15% (G2 vs. G3). Wilcoxon tests were performed to test for
deviation of individual participants from the group mean.
Results
Step one
MIB-1-LI results were all below 8% for G1 and above 30% for
G3 carcinomas. However, interobserver variability was substantial
for the G2 cases, values ranging between 5 and 30% for the same
cases (Figure 2). We found good to very good kappa values for
interobserver correlations over the entire group of ten carcinomas
(G1–G3, 0?56–0?72), but only poor to moderate correlations when
the analysis was limited to the five G2 carcinomas (kappas 0?17–
0?49, Figure 2). We calculated for each pathologist and each
tumor the fraction of MIB-1-LI results over the mean MIB-1-LI of
the whole group of five pathologists (Figure 3B,C). Significant
deviations from group mean values were found for two of the
pathologists (Figure 3B,C). The severity of the deviation of MIB-
1-LI results from group mean values tended to be more
pronounced for the data obtained by counting than by eyeballing
(Figure 3B,C).
To assess the impact of the immunostaining technique on MIB-
1-LI values, we expressed the values obtained by each pathologist
in local immunostains as fraction over central immunostains. We
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significantly lower values than the central laboratory (Figure 3A).
Kappa values showed good to very good intralaboratory
correlations. As expected, kappa values were higher for the ten
carcinomas then for the five G2 carcinomas (Table 1).
Step two
The study was then extended to 15 pathologists who were asked
to assess MIB-1-LI on three G2 carcinomas. Expressing each
pathologist’s MIB-1-LI values as fraction over the group mean
value, we found significant deviations from mean values for several
pathologists (Figure 4A–D). As in step 1, the severity of the
deviation of MIB-1-LI values from mean values was more
pronounced for the results obtained by counting than by
eyeballing. This is also reflected by the larger standard deviations
from the mean values for counted than for eyeballed data. Using
kappa statistics, we found very poor interobserver correlations
between the 15 pathologists (15 pathologists=raters, three
tumors=subjects, three grades=categories). The data were
slightly more consistent on centrally stained slides (kappas 0?04–
0?14) than on locally stained slides (kappa 0?01–0?04), but no
difference was seen by pre-defining the field of interest or by
counting MIB1-positive nuclei.
The immunostaining techniques applied by the central and the
peripheral laboratories are shown in Table 2. All but one
institution used one of four DAKO clones, in dilutions from ready-
to-use to 1:600. Pretreatments include pressure heat, pressure
cooking as well as EDTA and CC1 antibody retrieval solutions.
To assess the impact of the immunostaining technique on the
MIB-1-LI read-outs, we expressed MIB-1-LI values as fraction of
local immunostains over central immunostains (Figure 4E,G).
We identified two laboratories, in which the local immunostaining
technique yielded significantly lower MIB-1-LI values than central
immunostains and one laboratory that yielded higher values.
These differences were seen both in the analyses of the eyeballed
and the counted data. Kappa statistics showed very good
correlations between central and local immunostains for all three
tumors, when based on MIB1-data assessed by eyeballing (0?94,
0?82, and 0?71 for cases 1, 2, and 3, respectively) and, to a
somewhat lesser extent, by counting (0?93, 0?61, and 0?43).
When expressing the MIB-1-LI values obtained in self-selected
over values in pre-defined areas, we identified three pathologists
who apparently selected fields of interest that were significantly less
proliferative than the pre-defined areas (Figure 4F,H). However,
this phenomenon depended on the mode of MIB-1 assessment.
For two pathologists (Nu1 and Nu15), underestimation of MIB-1-
LI was seen only for eyeballed data, and for one pathologist
(Nu11), the underestimation was only seen for counted data.
Kappa statistics showed good to very good correlations between
self-selected and pre-defined areas for all three tumors, both for
eyeballed (0?83, 0?83, and 0?69 for cases 1, 2, and 3, respectively)
and for counted values (0?61, 0?83, and 0?83).
MIB-1-LI data as assessed by eyeballing showed a good
correlation with data assessed by counting MIB-1 positive nuclei:
kappa values for the three tumors were 0?77, 0?61, and 0?60 for
Figure 1. Color plate with 6 color images of MIB-1 immunostains of breast carcinomas. A: Six 150 mm6150 mm fields from MIB-1
immunostains of moderately differentiated breast carcinomas were selected so as to cover a wide spectrum of immunostaining intensities, each
image containing some intensely stained nuclei, some clearly negative nuclei, but also a spectrum of intermediate immunostaining intensities. The
participating pathologists were asked to count and circle the number of MIB-1 positive and MIB-1 negative nuclei for each image. B: The right part of
the figure shows the same plate once more, only that this time those nuclei were circled that were considered MIB-1 positive by all investigators
upon joint discussion. This plate was provided to the participants of the study along with the slides for step 3, with the aim to further reduce
interobserver variabilities in MIB-1-LI results.
doi:10.1371/journal.pone.0037379.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37379Figure 2. MIB-1-LI results of ten breast carcinomas read by five pathologists (represented by lines in different colors): The left
panels (A,B) depict the results obtained in centrally immunostained slides and the right panels (C,D) the results on locally
immunostained slides. The upper panels (A,C) are eyeballed and the lower panels (B,D) counted data. Despite marked variability between the five
observers, MIB-1-LI results were all below 8% for the two G1 carcinomas and above 30% for the three G3 carcinomas. Note that MIB-1-LI results varied
considerably for the five moderately differentiated carcinomas. Shown in grey is the zone deliminated by the 8% and 15% cut-offs used for
calculating the kappa scores for interobserver correlations.
doi:10.1371/journal.pone.0037379.g002
Figure 3. Variability of MIB-1-LI results (ten carcinomas, five pathologists): MIB-1-LI data obtained by five pathologists on
immunostained slides of five moderately differentiated breast carcinomas (G2, red circles) and five G1 and G3 carcinomas (yellow
circles), once assessed by counting the number of MIB-1 positive nuclei among 2000 tumor nuclei (left graph) and once by
eyeballing the LI (right graph). Mean values over the ten carcinomas are shown in horizontal bars and standard deviations in vertical bars. A. local
vs central immunostains: shown are fractions of MIB-1-LI results on locally immunostained slides over the results obtained on centrally
immunostained slides. The observers 3 and 5 significantly underrated MIB-1-LI on the slides immunostained in their own laboratory when compared
to the central laboratory (**P,0?01 Wilcoxon). B,C. individual pathologist vs group mean: shown are fractions of MIB-1-LI results by individual
pathologists over the mean value calculated for the group of fibve pathologists for each individual carcinoma. Note that the observer 1 tended to
significantly underrate MIB-1-LI when compared to the mean values obtained by the entire group of five pathologists (*P,0?05 and **P,0?01
Wilcoxon). Also note that the deviations from the group mean values tended to be smaller for the eyeballed than for the counted data.
doi:10.1371/journal.pone.0037379.g003
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and 0?65, 0?79, and 0?64 for locally immunostained slides.
We next asked the question whether the differences in MIB-1-LI
results between pathologists might be due to different individual
perceptions of what a MIB-1-positive nucleus looks like. We
assumed that those pathologists who consistently read higher MIB-
1-LI values should have a lower threshold, considering even faintly
stained nuclei as positive, and vice versa. All 15 pathologists were
hence asked to count positive nuclei in six images of MIB-1
immunostains (Figure 1A), and the distribution of MIB-1 counts
was comparable to the distribution of values obtained on the slides,
some pathologists counting considerably fewer nuclei than others
(Figure 5). However, when we performed linear regression
analyses of mean MIB-1-LI values rendered on the microscope
slides by each individual pathologist against his/her mean counts
rendered on the 6 color plates, we found no significant correlation:
Rho values were below 0?30 (Spearman; Figure 6), suggesting
that the interobserver variability could not be explained by
differences in threshold levels for what each pathologist consider as
a MIB-1 positive nuclei.
Step three
Four months after step 2, the same 15 pathologists were asked to
assess MIB-1-LI once more on the same three G2 carcinomas that
had been used for step 2, as well as on three new breast
carcinomas (G1, G2, G3). Interobserver variability, as calculated
in analogy to step 2, was not improved: kappa values were even
smaller than those in step 2 (kappa 0?01–0?04) and the standard
deviations of the mean values were in the same range as the ones
in step two (Figure 7A,C).
In the first and the second step of this study, we found that
certain pathologists tended to systematically over- or underrate
MIB-1 LI. We hence tested whether a «correction factor» could be
established by calculating the deviation of each individual
pathologist’s MIB-1-LI results from the group mean for the three
new carcinomas (table 3). However, when applying this
correction factor to the results of the initial three carcinomas,
the interobserver correlation did not improve, as evidence by
largely identical standard deviations from the mean values
(Figure 7B,D).
To assess the intra-observer variability of the MIB-1-LI values,
we plotted for each pathologist his/her values obtained during step
2 and again four month later (Figure 8). For some tumors and
some pathologists, MIB-1-LI values migrated from values between
5–10% to values above 25% and vice versa. We also calculated
kappa scores using the same cut-off values of 8% and 15% that
were used in the prior analyses. As shown in figure 8, the kappa
scores indicated very poor consistency. They were slightly higher
when MIB-1-LI were assessed in pre-defined areas within the
carcinomas (vs. self-selected areas), and when MIB-1-LI was
assessed by eyeballing (vs. counting). However, the chance that a
breast carcinoma which had been assigned an intermediary score
in step 2 of the study received the same intermediary score once
again by the same pathologist a few months later was between 5/
15 and 9/15 under the various conditions, barely superior to
throwing dice (expected value: 5/15).
Discussion
The principal outcome of this quality control effort is that
interobserver variability of MIB-1 labeling index in breast
carcinomas is (i) more problematic than we had expected, (ii)
not easily explained by obvious confounders such as the
immunostaining technique and the selection of the tumor area,
(iii) not reduced by (meticulous) counting versus (rapid) eyeballing,
and (iv) not improved by efforts to standardize what exactly are
MIB-1 positive nuclei and where and how to count them.
… interobserver variability of MIB-1 labeling index in breast cancer is
more problematic than we had expected. At first sight, assessing MIB-1-LI
appears as a simple task. We do it every day, and even when we
integrate various opinions on individual tumors around the
multiheaded microscope, we seem to quickly arrive at a number
that everyone can agree with. Kappa values for interobserver
consistencies for MIB-1-LI in different tumors are usually in the
range of 0?60–0?85, suggesting a good reliability of this marker
[13,17–20]. Indeed, in the first step of our study, we obtained
similarly ‘‘good’’ kappa values (0?56–0?72) on the ten breast
carcinomas whose degree of differentiation ranged from G1 to G3
carcinomas (figure 3). However, when only the five G2
carcinomas were considered, Kappa values fell to values between
0?17 and 0?49, reflecting poor to moderate agreement at best. This
is particularly worrisome because these are the carcinomas for
which oncologists hope to obtain guidance with our MIB-1-LI
values for their chemotherapy decisions [13,14]. It is hence in this
group of moderately differentiated carcinomas where our capacity
to reliably diagnose MIB-1-LI for individual patients is put to test.
…. not easily explained by obvious confounding factors. Even though we
found that immunostaining techniques, including pre-treatment
protocols and antibody dilutions varied tremendously between
laboratories, the comparison between MIB-1-LI on centrally and
locally stained slides showed only small and inconsistent variations,
both in the initial study with five observers and in the main study
with 15 observers. This finding does not support the proposition
that individual MIB-1 cut-offs should be established for each
individual laboratory in order to reflect differences in immuno-
staining techniques [21]. We then asked whether the choice of the
Table 1. Kappa values for rating scores.
G2-carcinomas (n=5) G1–G3 carcinomas (n=10)
p a t h o l o g i s t 12345 123 4 5
central vs. local immunostains
eyeballed data 0.76 0.76 0.40 1.00 0.28 0.89 0.89 0.69 1.00 0.68
counted data 0.40 0.76 0.76 1.00 0.54 0.69 0.89 0.89 1.00 0.87
eyeballed vs. counted data
central immunostains 0.62 1.00 0.78 0.54 0.21 0.80 1.00 0.89 0.78 0.66
local immunostains 0.17 1.00 1.00 0.29 0.00 0.60 1.00 1.00 0.67 0.49
doi:10.1371/journal.pone.0037379.t001
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‘‘excuse’’ when MIB-1-LI read-outs cannot be reproduced, for
instance when we review our colleagues’ cases for the weekly
tumor board. We adopted the view that proliferative activity
should be assessed in the proliferating active tumor periphery and
that - in contrast to earlier proposals [22] - hotspots should be
avoided. If the choice of the field of interest were to have exerted a
marked impact on interobserver variability, we should have found
significant deviations of MIB-1-LI between self-selected and pre-
defined fields of interest for several of the observers. However, this
was not the case. We found only small variations between self-
selected and pre-defined fields of interest. This observation is
supported by reports that variations between random fields
selected from within the growth zone of invasive breast carcinomas
are usually quite small [22–24].
…not reduced by (meticulous) counting versus (rapid) eyeballing. We have
often disputed whether MIB-1-LI should be counted (and if yes,
should we count 500, 1000, or even 2000 tumor cells) or whether it
is just as good to simply eyeball the labeling index. When
analysed side by side, both techniques yield similar results [25].
Yet, none seems to have ever systematically analyzed which of the
two methods yields more reproducible results. This may be
because there is no ‘‘truth’’ to compare with, or because the
answer seemed so very obvious: of course, counting ‘must be’
better than eyeballing. However, this is not what we observed in
our present study: eyeballing resulted in MIB-1-LI read-outs that
deviated much less from a central mean value than the counted
data. Eyeballing is typically done at a smaller magnification than
counting, making it easier to integrate slight locoregional
variations and to arrive at more consistent average values. The
smaller the field of interest, the higher the variability of computer-
assisted MIB-1 LI values [26]. Also, counting may so occupy our
brains that we may be less receptive for other important
information. Those who were in the audience will remember the
video clip shown at the 94
th annual meeting of the United States
and Canadian Academy of Pathology in San Antonio, where we
were all so busy counting how often a ball was bounced back and
forth between the players of the black team that most of us failed to
notice the huge black gorilla that slowly walked across the scene.
Even though the fact that eyeballing yields more reliable MIB-1-LI
results than counting may appear counter-intuitive at first sight,
there exists no similar study in the literature that suggests that this
should be different.
… not improved by efforts to standardize what exactly are MIB-1 positive
nuclei and where and how to count them. After having failed to identify
one or several confounding factors that could explain the high
Figure 4. Variability of MIB-1-LI results (three carcinomas, 15 pathologists): MIB-1-LI data obtained by 15 pathologists on
immunostained slides of three moderately differentiated breast carcinomas, assessed either by eyeballing the LI or by counting
the number of MIB-1 positive nuclei among 500 tumor nuclei. A–D Interobserver variabilities of MIB-1-LI results: Shown are the fraction of
MIB-1-LI results by individual pathologists over the mean value calculated for the entire group of 15 pathologists for this same carcinoma. Red and
yellow circles indicate results obtained in self- selected and predefined areas, respectively. Mean values are shown in horizontal bars. Shown are the
results obtained on centrally immunostained slides (A,C) and on locally immunostained slides (B,D). Several pathologists systematically under-rated
(pathologists 4,5 and 6) or over-rated MIB-1-LI (pathologists 8,14) when compared to the mean values obtained by the entire group of 15
pathologists (*P,0?05 and **P,0?01 Wilcoxon). Note that for the entire group of 15 pathologists, the standard deviations around the mean values
were smaller when MIB-1-LI were eyeballed (A,B, SD=21?7 and 24?2) as compared to the data that were obtained by counting MIB-1 postive nuclei
(C,D, SD=34?5 and 30?6). E,G impact of immunostaining technique: shown are for each carcinoma the fraction of MIB-1-LI data on locally
immunostained slides over those read on centrally immunostained slides. Red and yellow circles indicate results obtained in self- selected and
predefined areas, respectively. Mean values are shown in horizontal bars. The observers 1 and 2 significantly under-rated MIB-1-LI on the slides
immunostained in their own laboratory when compared to the central laboratory, suggesting that their immunostaining techniques yielded fainter
results than the one of the central laboratory (*P,0?05 and **P,0?01 Wilcoxon). Note that for the entire group of 15 pathologists, the standard
deviations around the mean values were slightly smaller when MIB-1-LI were eyeballed (E, SD=21?4) as compared to the data that were obtained by
counting MIB-1 positive nuclei among 500 tumor cells (G, SD=25?3). F,H impact of the tumor area: shown are for each carcinoma the fraction of MIB-
1-LI read-outs in areas that each pathologist had selected his/herself over read-outs repeated in areas that had been pre-selected by the principal
investigator. Red and yellow circles indicate results obtained in centrally and locally immunostained slides, respectively. Mean values are shown in
horizontal bars. For four of the 15 pathologists, there was a near perfect match between self-selected and pre-defined areas within the tumor. Overall,
there was a very small variability for the entire group of 15 pathologists.
doi:10.1371/journal.pone.0037379.g004
Table 2. Laboratory protocols for Ki-67 immunostains in the 12 participating pathology institutes.
Institution Antibody/Clone Pretreatment Dilution Detection System
1 DAKO/MIB-1 30 min, EDTA, pH 9 1:100 Leica Bond Max
2 DAKO/M7240 30 min, EDTA, CC1 1:50 Benchmark
3 DAKO/KI-67 90 sec,cooking, pH 9 1:500 Autostainer Plus
4 DAKO/M7240 30 min, standard CC1 1:40 Benchmark
5 Cell Marque/KI-67 (SP6) 90 sec, pressure heat 1:100 Benchmark
6 DAKO/KI-67 30 min, pressure heat 1:500 Leica Bond Max
7 DAKO/KI-67 90 sec, cooking 1:600 Autostainier Plus
8 DAKO/M7240 30 min, CC1 standard 1:20 Benchmark
9 DAKO/KI-67 30 min, ER1 buffer, pH 6 1:50 Bond Diluent
10 DAKO/MM1 30 min, ER2 buffer Ready to use Leica Bond Max
11 DAKO/KI-67 30 min, EDTA, pH 9 1:200 Leica Bond Max
12 DAKO/M7240 30 min, CC1 standard 1:40 Benchmark
doi:10.1371/journal.pone.0037379.t002
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had divergent notions of how a MIB-1-positive nucleus looks like.
After all, there exists a spectrum of immunostaining intensities in
MIB-1 immunohistochemistry, ranging from homogeneously
dark-brown dots all the way down to lightly speckled nuclei. For
this reason, we asked the participating pathologists to mark on an
‘‘intensity plate’’ to identify positive nuclei. No need to calculate
percentages, just count. Some of us counted considerably fewer
nuclei than others, obviously considering only the very dark nuclei
as positive while the rest of us counted also the slightly stained
nuclei as positive, as proposed by several authors [7,17,24]. We
then reasoned that those colleagues who counted only the very
dark nuclei should also be those who had under-estimated MIB-1-
LI in our interobserver correlation analysis and vice versa. So, we
plotted the number of positive nuclei counted on the ‘‘intensity
plates’’ against the MIB-1-LI read-outs, but found no significant
correlation suggesting that the interobserver variability could not
be explained by different ideas of what counts as how a MIB-1
positive nucleus should look like.
In a similar study on paediatric sarcomas, Molenaar and co-
workers arrived at the conclusion that a major part of the
variability of MIB-1-LI remains unexplained, and suggested two
ways to improve interobserver reliability: (i) systematic training (i.e.
to standardize the tumor areas in which to look) and (ii) a
Figure 5. How does a MIB-1 positive nucleus look like? MIB-1-positive cells counted by the 15 pathologists on the 6 high power
fields shown in figure 1A. The 16th bar in red shows the counts provided by Pr. Giuseppe Viale who helped us standardize which nuclei should be
considered MIB-1-positive in the right panel of figure 1 (1B). Note that several pathologists counted only those nuclei that were intensely
immunostained (pathologists 8,11,14), while most included in their count also most faintly immunostained nuclei. Note that the results were very
homogeneous for the 6 different high power fields.
doi:10.1371/journal.pone.0037379.g005
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of our study we aimed to test these two avenues. We reasoned that
through intensive intellectual confrontation with the subject matter
(i.e. discussions of the results in the working group and at the
annual conference of our society) and through improved
standardization, we could obtain more consistent MIB-1-LI
results. In analogy to the well-publicised DAKO plates depicting
typical images of the three degrees of Her2/neu positivity (+, ++,
+++), we distributed to the participating pathologists the six panel
‘‘intensity’’ plate on which we had circled all those nuclei that we
had jointly defined as MIB-1 positive. Four months after the
interobserver correlation study on the three moderately differen-
tiated carcinomas (step 2), we sent the same three G2 carcinomas
to the 15 pathologists again for MIB-1-LI reading. In addition,
three new carcinomas (G1, G2, and G3) were sent included. As
proposed by Molenaar and co-workers [27], we wanted to use the
MIB-1-LI read-outs on these three new cases to calculate for each
pathologist a ‘‘correction factor’’ (individual result/group mean)
and test whether the interobserver variability of the three initial
G2 carcinomas could be reduced by this simple mathematical
manoever. However, the kappa values in this third round were
even lower than in round two and we even obtained negative
Kappa values, suggesting that our interobserver consistency was
worse than throwing dice. Also, each individual pathologist’s intra-
observer consistency between MIB-1-LI results obtained initially
and three months later on the same three tumors was scarcely
better than throwing dice. Taken together, these findings do not
support the proposition that interobserver variability can be
reduced by prior efforts to obtain consensus regarding methods
and appropriate interpretation of staining positivity [27,28].
We hence have to assume that our capacity to reproducibly
identify the percentage of MIB-1 positive tumor cells is likely
governed by factors that reside in the largely undiscovered realm
of cognitive psychology (affected by experience, expectation, bias,
etc…) and cannot easily be improved by intellectual efforts to
standardize the read-out technique [12,29,30]. For practical
purposes, if a G2 carcinoma is read out by a particular pathologist
as 24%, does that reliably mean that the patient will benefit from
Figure 6. Absence of linear correlations between the MIB-1 counts obtained in the 6 high power fields (figure 1) and the MIB-1-LI
results obtained on the three moderately differentiated carcinomas (figure 4). The linear correlations were calculated separately for data
obtained by eyeballing (upper panels, A,C) and by counting (lower panels, B,D) and for data obtained on centrally immunostained slides (left panels,
A,B) and on locally immunostained slides (right panels, C,D). This analysis was done in order to test the hypothesis that under-raters (i.e. pathologists
4,5, and 6 in figure 4) considered only very intensely immunostained nuclei as positive and vice versa. However, this hypothesis was proven wrong:
we found no significant linear correlations between the MIB-1-LI results on the three carcinomas and the number of MIB-1 positive nuclei counted by
the same 15 pathologists in the 6 panel plate.
doi:10.1371/journal.pone.0037379.g006
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37379Figure 7. Interobserver variabilities in MIB-1-LI results, four months later: MIB-1-LI data obtained by 15 pathologists on centrally
immunostained slides of three moderately differentiated breast carcinomas, assessed by eyeballing (A,B) and counting (C,D).
Shown are for each pathologist the fraction of MIB-1-LI results over the mean value calculated for the entire group of 15 pathologists. Red and yellow
circles indicate results obtained in self- selected and predefined areas, respectively. Mean values are shown in horizontal bars. The interobserver
variabilities were comparable to the results obtained four months prior on the same slides (see figure 4B). The data shown in the right panels (B,D)
were then modified by a ‘‘correction factor’’ for each individual pathologist. This correction factor was calculated from the results obtained on three
independent carcinomas, see Table 3). Yet, this correction factor could not reduce the high interobserver variability, as evidenced by only slight
reductions of the standard deviations (27?8v s3 0 ?4 for eyeballed and 22?5v s2 4 ?1 for counted data).
doi:10.1371/journal.pone.0037379.g007
Table 3. Step three, Ki-67 mean values (6 carcinomas, 15 pathologists).
central immunostains
assessment by eyeballing assessment by counting
self-selected areas predefined areas self-selected areas predefined areas
Case 1 (%) 13.966.8 14.264.5 13.764.4 14.663.6
corrected 15.066.9 14.965.8 14.364.6 13.764.3
Case 2 (%) 11.366.5 11.566.6 10.764.3 11.263.6
corrected 11.165.2 11.365.3 11.262.9 11.662.8
Case 3 (%) 15.564.3 12.963.9 15.066.5 14.265.2
corrected 16.968.5 13.264.3 12.565.0 13.764.2
Case 4 (%) 3.462.0 3.162.0 3.562.1 2.761.3
Case 5 (%) 12.564.3 12.064.6 12.664.6 12.263.9
Case 6 (%) 22.966.4 23.164.8 25.665.2 25.166.2
doi:10.1371/journal.pone.0037379.t003
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PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37379chemotherapy? Our study suggests that the same tumor might just
as well have been signed out as 10% or 35% by another
pathologist or by the same pathologist four months later. For the
future, we might consider using computer-based image analysis,
which has been found to yield more consistent MIB-1-LI results in
GISTs [31], dysplasias in Barrett’s esophagus [32], sarcomas [33],
and breast carcinomas [23,34–36]. However, beside variations
during the digitization of slides, definition of positivity cut-offs and
the reliable identification of ‘‘negative’’ cells (stroma vs. lympho-
cytes vs. tumor cells), computer-based image analysis harbors
other distinct logistical problems (costs, time and manpower). This
may eventually change with the availability of easily applicable
open source techniques [37].
In conclusion, even though Kappa values have suggested that
interobserver reliability of MIB-1-LI read-outs over a wide range
of tumor differentiations is good, this promise appears not to hold
true for those intermediately differentiated G2 carcinomas where
oncologists would salute this marker as guidance for their
treatment decisions in individual patients.
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